Published in Atherosclerosis on August 31, 2007
PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res (2008) 3.92
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 1.65
The PCSK9 decade. J Lipid Res (2012) 1.50
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet (2015) 1.50
PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep (2008) 1.17
Lipoproteins, cholesterol homeostasis and cardiac health. Int J Biol Sci (2009) 0.97
Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev (2008) 0.89
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol (2015) 0.85
On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis (2014) 0.82
Hypocholesterolemic and Antiatherosclerotic Potential of Basella alba Leaf Extract in Hypercholesterolemia-Induced Rabbits. Evid Based Complement Alternat Med (2015) 0.81
Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. J Biol Chem (2015) 0.78
Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat. BMC Cardiovasc Disord (2014) 0.76
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases. Scientifica (Cairo) (2012) 0.76
Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med (2008) 14.01
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet (2011) 5.61
Antiinflammatory properties of HDL. Circ Res (2004) 5.41
Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.92
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52
Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int (2010) 3.37
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest (2003) 3.09
Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int (2011) 3.05
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation (2011) 3.01
ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol (2005) 2.46
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med (2007) 2.41
A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med (2011) 2.22
Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity (Silver Spring) (2009) 2.07
Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem (2003) 2.04
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis (2006) 1.99
Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol (2003) 1.94
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol (2005) 1.91
High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol (2006) 1.84
Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol (2006) 1.84
Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res (2005) 1.79
Health benefits of herbs and spices: the past, the present, the future. Med J Aust (2006) 1.76
Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis (2010) 1.76
The metabolism and anti-atherogenic properties of HDL. J Lipid Res (2008) 1.74
The global cardiovascular diseases risk pattern in a peri-urban working-class community in South Africa. The Mamre study. Ethn Dis (2004) 1.73
Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci U S A (2008) 1.71
The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci U S A (2001) 1.61
What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol (2005) 1.61
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem (2006) 1.60
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem (2008) 1.56
Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol (2010) 1.55
Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation (2011) 1.55
Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol (2009) 1.53
Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation (2005) 1.53
Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I. Cardiovasc Res (2011) 1.51
Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation (2011) 1.51
High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50
Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.50
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet (2015) 1.50
Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis (2011) 1.50
Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc Drugs Ther (2009) 1.49
Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr (2009) 1.49
Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. Clin Sci (Lond) (2006) 1.47
Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. Eur Heart J (2005) 1.46
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res (2012) 1.46
Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol (2007) 1.43
Effect of treatment on ventricular function and troponin I proteolysis in reperfused myocardium. J Mol Cell Cardiol (2002) 1.43
High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) (2009) 1.43
Plasma phospholipid transfer protein activity, a determinant of HDL kinetics in vivo. Clin Endocrinol (Oxf) (2006) 1.42
Coronary plaque regression: role of low density lipoprotein-apheresis. J Am Coll Cardiol (2002) 1.41
Prospective validation of cerebrospinal fluid bilirubin in suspected subarachnoid haemorrhage. Ann Clin Biochem (2007) 1.40
Reducing CVD risk - integration of clinical and laboratory criteria. Aust Fam Physician (2008) 1.39
On reducing cardiovascular disease to a rarity: clinical strategies and their cost-effectiveness. Heart Lung Circ (2010) 1.38
Coenzyme Q10: an independent predictor of mortality in chronic heart failure. J Am Coll Cardiol (2008) 1.35
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol (2010) 1.33
Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol (2005) 1.32
Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol (2007) 1.31
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol (2007) 1.30
Cardioprotective functions of HDLs. J Lipid Res (2013) 1.29
Molecular basis of PCSK9 function. Atherosclerosis (2008) 1.29
Prevalence of HIV and hepatitis C virus infections among inmates of Quebec provincial prisons. CMAJ (2007) 1.27
Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Biol (2012) 1.27
New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep (2007) 1.26
Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis (2013) 1.26
Disruption of the Arnt gene in endothelial cells causes hepatic vascular defects and partial embryonic lethality in mice. Hepatology (2006) 1.24
Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr (2003) 1.23
Contamination of Qiagen DNA extraction kits with Legionella DNA. J Clin Microbiol (2003) 1.22
ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem (2008) 1.20
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation (2013) 1.20
Disruption of hepatic C/EBPalpha results in impaired glucose tolerance and age-dependent hepatosteatosis. J Biol Chem (2004) 1.20
Recommendations for lipid testing and reporting by Australian pathology laboratories. Clin Biochem Rev (2007) 1.19
The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol (2009) 1.19
The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol (2012) 1.17
Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. J Biol Chem (2004) 1.17
Cystatin C--a paradigm of evidence based laboratory medicine. Clin Biochem Rev (2008) 1.17
High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol (2010) 1.16
Cholesterol metabolism and pancreatic beta-cell function. Curr Opin Lipidol (2009) 1.16
Double complex mutations involving F8 and FUNDC2 caused by distinct break-induced replication. Hum Mutat (2007) 1.15
Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol (2010) 1.15